160 related articles for article (PubMed ID: 14504207)
1. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.
Plummer SJ; Conti DV; Paris PL; Curran AP; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 2003 Sep; 12(9):928-32. PubMed ID: 14504207
[TBL] [Abstract][Full Text] [Related]
2. The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose.
Dally H; Edler L; Jäger B; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Schulz V; Kayser K; Bartsch H; Risch A
Pharmacogenetics; 2003 Oct; 13(10):607-18. PubMed ID: 14515059
[TBL] [Abstract][Full Text] [Related]
3. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.
Zeigler-Johnson C; Friebel T; Walker AH; Wang Y; Spangler E; Panossian S; Patacsil M; Aplenc R; Wein AJ; Malkowicz SB; Rebbeck TR
Cancer Res; 2004 Nov; 64(22):8461-7. PubMed ID: 15548719
[TBL] [Abstract][Full Text] [Related]
4. Genetic association in
Bellah SF; Salam MA; Billah SMS; Karim MR
Ann Hum Biol; 2023 Feb; 50(1):63-74. PubMed ID: 36688864
[TBL] [Abstract][Full Text] [Related]
5. Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men.
Bangsi D; Zhou J; Sun Y; Patel NP; Darga LL; Heilbrun LK; Powell IJ; Severson RK; Everson RB
Urol Oncol; 2006; 24(1):21-7. PubMed ID: 16414488
[TBL] [Abstract][Full Text] [Related]
6. Genetic contribution to variable human CYP3A-mediated metabolism.
Lamba JK; Lin YS; Schuetz EG; Thummel KE
Adv Drug Deliv Rev; 2002 Nov; 54(10):1271-94. PubMed ID: 12406645
[TBL] [Abstract][Full Text] [Related]
7. CYP3A4 and CYP3A5 genotyping by Pyrosequencing.
Garsa AA; McLeod HL; Marsh S
BMC Med Genet; 2005 May; 6():19. PubMed ID: 15882469
[TBL] [Abstract][Full Text] [Related]
8. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients.
Paris PL; Kupelian PA; Hall JM; Williams TL; Levin H; Klein EA; Casey G; Witte JS
Cancer Epidemiol Biomarkers Prev; 1999 Oct; 8(10):901-5. PubMed ID: 10548319
[TBL] [Abstract][Full Text] [Related]
9. Differences in CYP3A5*3 genotype distribution and combinations with other polymorphisms between Spaniards and Other Caucasian populations.
Gervasini G; Vizcaino S; Gasiba C; Carrillo JA; Benitez J
Ther Drug Monit; 2005 Dec; 27(6):819-21. PubMed ID: 16306861
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Loukola A; Chadha M; Penn SG; Rank D; Conti DV; Thompson D; Cicek M; Love B; Bivolarevic V; Yang Q; Jiang Y; Hanzel DK; Dains K; Paris PL; Casey G; Witte JS
Eur J Hum Genet; 2004 Apr; 12(4):321-32. PubMed ID: 14560315
[TBL] [Abstract][Full Text] [Related]
11. Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Han JH; Lee YS; Kim HJ; Lee SY; Myung SC
Asian J Androl; 2015; 17(2):285-91. PubMed ID: 25337833
[TBL] [Abstract][Full Text] [Related]
12. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Gervasini G; García-Martín E; Ladero JM; Pizarro R; Sastre J; Martínez C; García M; Diaz-Rubio M; Agúndez JA
BMC Cancer; 2007 Jul; 7():118. PubMed ID: 17605821
[TBL] [Abstract][Full Text] [Related]
13. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
14. Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population.
Islam MS; Mostofa AG; Ahmed MU; Bin Sayeed MS; Hassan MR; Hasnat A
Tumour Biol; 2014 Feb; 35(2):1671-8. PubMed ID: 24085358
[TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.
He P; Court MH; Greenblatt DJ; Von Moltke LL
Clin Pharmacol Ther; 2005 May; 77(5):373-87. PubMed ID: 15900284
[TBL] [Abstract][Full Text] [Related]
16. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients.
Lepper ER; Baker SD; Permenter M; Ries N; van Schaik RH; Schenk PW; Price DK; Ahn D; Smith NF; Cusatis G; Ingersoll RG; Bates SE; Mathijssen RH; Verweij J; Figg WD; Sparreboom A
Clin Cancer Res; 2005 Oct; 11(20):7398-404. PubMed ID: 16243813
[TBL] [Abstract][Full Text] [Related]
17. CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.
Keshava C; McCanlies EC; Weston A
Am J Epidemiol; 2004 Nov; 160(9):825-41. PubMed ID: 15496535
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.
Jin M; Gock SB; Jannetto PJ; Jentzen JM; Wong SH
J Anal Toxicol; 2005 Oct; 29(7):590-8. PubMed ID: 16419387
[TBL] [Abstract][Full Text] [Related]
19. Significance of the minor cytochrome P450 3A isoforms.
Daly AK
Clin Pharmacokinet; 2006; 45(1):13-31. PubMed ID: 16430309
[TBL] [Abstract][Full Text] [Related]
20. Genotype relationships in the CYP3A locus in Caucasians.
Dally H; Bartsch H; Jäger B; Edler L; Schmezer P; Spiegelhalder B; Dienemann H; Drings P; Kayser K; Schulz V; Risch A
Cancer Lett; 2004 Apr; 207(1):95-9. PubMed ID: 15050738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]